Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults and children age 2 or older with locally advanced or metastatic RET fusion-positive solid tumors confirmed by an FDA-approved test, after progression on or following systemic treatment or when satisfactory alternatives are unavailable.
LAMPGEN ANALYSIS
Why it matters
The traditional approval supports a tumor-agnostic RET fusion indication across age groups. Distinguish the broad label from the specific tumor and pediatric cohorts that informed the decision.
What research teams should watch
Record the RET fusion and assay, prior therapy and age cohort. For rare alterations, referral and tissue access can shape how many patients are identified.
PRIMARY RECORDS